24/7 Market News Snapshot 21 January, 2025 – Dogwood Therapeutics, Inc. Common Stock (NASDAQ:DWTX)

January 21, 2025

DENVER, Colo., 21 January, 2025 (247marketnews.com) – (NASDAQ:DWTX) are discussed in this article.
Dogwood Therapeutics, Inc. (DWTX) is currently experiencing a significant surge in its stock value, trading at $2.512, marking an increase of 34.33% from the previous closing price of $1.870. This positive momentum has drawn considerable investor interest, reflected in a robust trading volume of 6.83 million shares. Analysts are closely monitoring this biotech firm for additional developments as it capitalizes on current market trends.

In tandem with its impressive stock performance, Dogwood Therapeutics has announced the upcoming initiation of patient dosing in its Phase 2b clinical trial, HALT-CINP, which targets neuropathic pain related to chemotherapy treatment. The first patient is expected to be dosed in the first quarter of 2025, signaling a pivotal advancement in the company’s efforts to provide innovative non-opioid pain management solutions.

Halneuron®, the company’s flagship product candidate, operates as a Nav 1.7 sodium channel inhibitor and has shown promising results in earlier Phase 2 trials, effectively reducing cancer-related pain with a favorable safety profile. R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer, highlighted that approximately one-third of patients undergoing chemotherapy with certain agents experience chronic neuropathy. With no currently approved treatment options for chemotherapy-induced neuropathic pain, Halneuron® addresses a pressing medical need.

CEO Greg Duncan noted the substantial market potential, estimating the chronic neuropathy sector’s value at approximately $1.5 billion. He expressed confidence in the company’s ability to tackle this unmet need, aided by a seasoned executive team with a track record in developing leading pain medications.

In addition to Halneuron®, Dogwood Therapeutics is advancing several other therapeutic candidates, including an antiviral program targeting dormant herpes viruses. The company anticipates sharing interim data from the HALT-CINP trial in the latter half of 2025, reaffirming its commitment to improving patient outcomes through groundbreaking treatment options.

Related news for (DWTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.